ANTIMYCOBACTERIAL-DRUGS.pptx
•Download as PPTX, PDF•
1 like•32 views
This document discusses various antimycobacterial drugs used to treat tuberculosis and leprosy. It covers first-line drugs like isoniazid and rifampin that are commonly used to treat tuberculosis, as well as alternative second-line drugs that may be used when drug resistance develops. It also discusses drugs used to treat leprosy, including dapsone and clofazimine, providing information on their mechanisms of action, resistance, pharmacokinetics, and adverse effects.
Report
Share
Report
Share
Recommended
Sk amd
The document discusses antimicrobial drug resistance (AMDR) and the mechanisms by which microbes develop resistance to antimicrobial medications. It describes classes of AMDR including resistance to antifungal, antiviral, antiprotozoal, and antibacterial drugs. Mechanisms of resistance include altering drug receptors or targets, reducing drug accumulation in cells, inactivating drugs, and developing resistant metabolic pathways. The document also summarizes the cellular and molecular mechanisms of antimicrobial action, including interfering with cell wall synthesis, plasma membrane integrity, nucleic acid synthesis, ribosomal function, and folate synthesis.
Antimycobacterial Drugs.pptx
This document discusses antimycobacterial drugs used to treat tuberculosis, leprosy, and other mycobacterial infections. It describes the mechanisms of action, pharmacokinetics, clinical uses, and toxicities of major drugs including isoniazid, rifampin, ethambutol, pyrazinamide, streptomycin, and alternative drugs. It also discusses drug regimens for treating drug-susceptible and drug-resistant forms of tuberculosis, as well as drugs used to treat leprosy such as dapsone and sulfones.
Drugs for tuberculosis
The document discusses drugs used for treating tuberculosis and related mycobacterial infections. It provides learning outcomes on first-line and second-line antitubercular drugs, their mechanisms of action, mechanisms of resistance, pharmacokinetics, and management of tuberculosis. The first section introduces commonly used first-line drugs like isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. The second section covers second-line drugs and new drugs like bedaquiline used for multidrug-resistant tuberculosis. The last section discusses principles of antituberculosis chemotherapy and types of treatment including prophylaxis and therapy for drug-susceptible and drug-resistant tuberculosis.
drug used
The document summarizes first-line and second-line drugs used to treat tuberculosis. It describes the mechanisms of action, resistance mechanisms, clinical uses, and adverse effects of isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin as first-line agents. It then discusses second-line drugs used to treat multi-drug resistant tuberculosis, including ethionamide, capreomycin, cycloserine, aminosalicylic acid, fluoroquinolones, linezolides, and rifabutin.
Sulfonamides. anti-mycobacterial drugs
G. Domagk discovered the first sulfonamide in 1935 and won the Nobel Prize in 1939. Sulfonamides are structurally similar to PABA and inhibit the enzyme dihydrofolate synthetase, blocking the biosynthesis of folic acid in bacteria. They have bacteriostatic activity against a wide range of microorganisms. Common adverse effects include rashes, crystalluria with overdose, and hemolysis in G6PD deficient patients. Resistance is transmitted by plasmids in some bacteria.
Drugs used-in-tuberculosis-1228195316676830-9
This document discusses first-line and second-line drugs used to treat tuberculosis, including multi-drug resistant tuberculosis. First-line drugs include isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. Second-line drugs used when resistance develops include ethionamide, capreomycin, cycloserine, aminosalicylic acid, fluoroquinolones, kanamycin, amikacin, linezolides, rifabutin, and rifapentine. Resistance can develop through mutations that impair drug uptake or target sites. Many second-line drugs have toxic side effects like nephrotoxicity or ototoxicity that require monitoring.
Anti-Tuberculous & Anti-leprosy drugs
This document discusses anti-tuberculosis drugs and their use in treating tuberculosis (TB) and leprosy. It outlines the first-line drugs used to treat TB, including isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin. It describes their mechanisms of action, therapeutic uses, and potential adverse effects. The document also discusses second-line drugs and treatment regimens for both active and latent TB. Finally, it covers the drugs used to treat leprosy, including dapsone, clofazimine, and rifampin.
Anti-Viral Drugs new.pptx
This document summarizes several classes of anti-viral drugs, including their mechanisms of action, pharmacokinetics, adverse effects, and resistance. It discusses neuraminidase inhibitors oseltamivir and zanamivir for influenza, M2 protein inhibitors amantadine and rimantadine, ribavirin which is effective against many RNA and DNA viruses, anti-virals for hepatitis like interferon, acyclovir for herpes infections, and various drugs used to treat HIV infections including NRTIs, NNRTIs, and protease inhibitors. The document provides details on the targets and modes of action of these anti-virals.
Recommended
Sk amd
The document discusses antimicrobial drug resistance (AMDR) and the mechanisms by which microbes develop resistance to antimicrobial medications. It describes classes of AMDR including resistance to antifungal, antiviral, antiprotozoal, and antibacterial drugs. Mechanisms of resistance include altering drug receptors or targets, reducing drug accumulation in cells, inactivating drugs, and developing resistant metabolic pathways. The document also summarizes the cellular and molecular mechanisms of antimicrobial action, including interfering with cell wall synthesis, plasma membrane integrity, nucleic acid synthesis, ribosomal function, and folate synthesis.
Antimycobacterial Drugs.pptx
This document discusses antimycobacterial drugs used to treat tuberculosis, leprosy, and other mycobacterial infections. It describes the mechanisms of action, pharmacokinetics, clinical uses, and toxicities of major drugs including isoniazid, rifampin, ethambutol, pyrazinamide, streptomycin, and alternative drugs. It also discusses drug regimens for treating drug-susceptible and drug-resistant forms of tuberculosis, as well as drugs used to treat leprosy such as dapsone and sulfones.
Drugs for tuberculosis
The document discusses drugs used for treating tuberculosis and related mycobacterial infections. It provides learning outcomes on first-line and second-line antitubercular drugs, their mechanisms of action, mechanisms of resistance, pharmacokinetics, and management of tuberculosis. The first section introduces commonly used first-line drugs like isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. The second section covers second-line drugs and new drugs like bedaquiline used for multidrug-resistant tuberculosis. The last section discusses principles of antituberculosis chemotherapy and types of treatment including prophylaxis and therapy for drug-susceptible and drug-resistant tuberculosis.
drug used
The document summarizes first-line and second-line drugs used to treat tuberculosis. It describes the mechanisms of action, resistance mechanisms, clinical uses, and adverse effects of isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin as first-line agents. It then discusses second-line drugs used to treat multi-drug resistant tuberculosis, including ethionamide, capreomycin, cycloserine, aminosalicylic acid, fluoroquinolones, linezolides, and rifabutin.
Sulfonamides. anti-mycobacterial drugs
G. Domagk discovered the first sulfonamide in 1935 and won the Nobel Prize in 1939. Sulfonamides are structurally similar to PABA and inhibit the enzyme dihydrofolate synthetase, blocking the biosynthesis of folic acid in bacteria. They have bacteriostatic activity against a wide range of microorganisms. Common adverse effects include rashes, crystalluria with overdose, and hemolysis in G6PD deficient patients. Resistance is transmitted by plasmids in some bacteria.
Drugs used-in-tuberculosis-1228195316676830-9
This document discusses first-line and second-line drugs used to treat tuberculosis, including multi-drug resistant tuberculosis. First-line drugs include isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. Second-line drugs used when resistance develops include ethionamide, capreomycin, cycloserine, aminosalicylic acid, fluoroquinolones, kanamycin, amikacin, linezolides, rifabutin, and rifapentine. Resistance can develop through mutations that impair drug uptake or target sites. Many second-line drugs have toxic side effects like nephrotoxicity or ototoxicity that require monitoring.
Anti-Tuberculous & Anti-leprosy drugs
This document discusses anti-tuberculosis drugs and their use in treating tuberculosis (TB) and leprosy. It outlines the first-line drugs used to treat TB, including isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin. It describes their mechanisms of action, therapeutic uses, and potential adverse effects. The document also discusses second-line drugs and treatment regimens for both active and latent TB. Finally, it covers the drugs used to treat leprosy, including dapsone, clofazimine, and rifampin.
Anti-Viral Drugs new.pptx
This document summarizes several classes of anti-viral drugs, including their mechanisms of action, pharmacokinetics, adverse effects, and resistance. It discusses neuraminidase inhibitors oseltamivir and zanamivir for influenza, M2 protein inhibitors amantadine and rimantadine, ribavirin which is effective against many RNA and DNA viruses, anti-virals for hepatitis like interferon, acyclovir for herpes infections, and various drugs used to treat HIV infections including NRTIs, NNRTIs, and protease inhibitors. The document provides details on the targets and modes of action of these anti-virals.
Rifampicin ppt. ravi (medicinal chemistry)
Rifampicin is a semi-synthetic antibiotic produced from Rifamycin-B that is used to treat tuberculosis and other bacterial infections. It works by binding to DNA-dependent RNA polymerase in bacteria, preventing RNA synthesis and protein synthesis. For tuberculosis treatment, rifampicin is used in combination with other drugs in a multi-drug therapy regimen to reduce development of drug resistance. It has good solubility and selectively targets bacterial cells over mammalian cells.
Antitubercular agents (Anti-TB agents)
1. Tuberculosis remains a major global health problem, causing millions of deaths each year. New antitubercular agents are needed to combat drug resistance.
2. The document discusses the development of various classes of antitubercular agents, including synthetic drugs like isoniazid and rifampin, and antibiotics such as streptomycin. It covers their mechanisms of action, effectiveness, and toxicity.
3. Classification of antitubercular drugs includes first-line agents that are most effective and least toxic, second-line alternatives for resistant cases, and third-line options that are least effective and most toxic. Developing improved drug combinations remains a priority area in tuberculosis treatment.
Rifampicin ppt
Rifampicin is a broad-spectrum antibiotic used to treat tuberculosis and other bacterial infections. It works by inhibiting bacterial RNA polymerase, preventing RNA transcription and blocking bacterial growth. Rifampicin is well absorbed orally and widely distributed throughout the body, including crossing the blood-brain barrier. It is metabolized in the liver and mainly eliminated through bile with some excretion in urine. Common side effects include upset stomach, headache, and red/orange discoloration of bodily fluids. Rifampicin may interact adversely with some antiviral, anticoagulant, anti-convulsant and hypoglycemic drugs. It is an important first-line treatment for tuberculosis but requires combination therapy to prevent development
Antiviral HIV ARVS AIDS RETROVIRAL
antiviral,hiv,aids,drugs,infection,cmv,Nonnucleoside,Protease,Integrase,Herpes simplex,Cytomegalovirus,Influenza,immunodeficiency,haart,antiretroviral
mondalanti-viral_drugs_f09.pdf
- The document discusses various antiviral drugs used to treat different viral infections like influenza, herpes simplex virus, cytomegalovirus, hepatitis B, respiratory syncytial virus, and HIV. It provides details on the mechanism of action, pharmacokinetics, therapeutics, and side effects of drugs like amantadine, rimantadine, zanamivir, oseltamivir, acyclovir, ganciclovir, ribavirin, interferons, and lamivudine. It also lists alternative drugs that can be used if the primary drug develops resistance or has unacceptable side effects.
Chapter 10 anti-tb, art...
This document discusses antimycobacterial agents used for treating tuberculosis and leprosy. It notes that mycobacterial infections present challenges as the microbes are slow-growing, can become dormant, and have a lipid-rich cell wall impermeable to many agents. Effective treatment requires prolonged, combined drug regimens to eliminate both actively dividing and resting bacteria and prevent emergence of resistance. First-line agents discussed include isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. Adverse effects and mechanisms of action are summarized for each. The document also outlines chemotherapy phases and available drug formulations in Ethiopia.
ANTIMICROBIALS/ ANTIBIOTICS : GENERAL CONSIDERATIONS
Antimicrobial drugs are classified in several ways including based on their chemical structure, mechanism of action, type of organism they target, and spectrum of activity. Some key issues that can arise with antimicrobial use include toxicity, hypersensitivity reactions, drug resistance, and superinfections. When choosing an antimicrobial, factors related to the patient like age, renal/liver function, drug allergies, and pregnancy status must be considered along with drug-related factors like spectrum of activity, toxicity profile, cost, and clinical evidence. The optimal antimicrobial must balance efficacy with safety for each individual patient.
RIFAMPICIN [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
RIFAMPICIN SOURCE, STRUCTURES,MECHANISM OF ACTION,SAR,RIFAMYCINS, USES HOW T.B IS TREATED?
BY P. RAVISANKAR
VIGNAN PHARMACY COLLEGE
VADLAMUDI
GUNTUR,
ANDHRA PRADESH
INDIA.
TB and Leprosy.pptx
Leprosy
Tuberculosis
TYB pharmacy
Pharmacology semester VI notes
Pharmacology VI semester
Pharmacology notes
Third year B pharmacy pharmacology notes
Pharmacology unit 3 notes
Pharmacology VI semester notes
Anti tb drugs cbme 2021 satya
This interesting ppt contains Anti TB drugs topic for II MBBS CBME students Illustrated with pictures and flowcharts..
Primary headache
The document provides an overview of the classification and treatment of primary headaches according to the International Headache Society. It discusses the four main categories of primary headache - migraine, tension-type headache, trigeminal autonomic cephalalgias (TACs), and other headaches. For each category, it provides the diagnostic criteria and recommendations for treatment, including acute and preventive pharmacological management. The treatment sections cover over-the-counter and prescription medications such as NSAIDs, triptans, antidepressants, anticonvulsants, and other therapeutic options.
Tuberculosis
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and commonly affects the lungs. It can be transmitted through airborne droplets when an infected person coughs or sneezes. TB is diagnosed through chest x-rays, sputum examination, tuberculin tests, and PCR analysis. The first-line drugs isoniazid, rifampin, pyrazinamide, and ethambutol are used to treat TB according to standard 6-month regimens recommended by the WHO. These drugs work by inhibiting cell wall synthesis and other critical bacterial processes. While generally safe, they can cause adverse effects like hepatitis, rashes, and neuropathy, requiring monitoring during treatment.
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Context. The observation of several L-band emission sources in the S cluster has led to a rich discussion of their nature. However, a definitive answer to the classification of the dusty objects requires an explanation for the detection of compact Doppler-shifted Brγ emission. The ionized hydrogen in combination with the observation of mid-infrared L-band continuum emission suggests that most of these sources are embedded in a dusty envelope. These embedded sources are part of the S-cluster, and their relationship to the S-stars is still under debate. To date, the question of the origin of these two populations has been vague, although all explanations favor migration processes for the individual cluster members. Aims. This work revisits the S-cluster and its dusty members orbiting the supermassive black hole SgrA* on bound Keplerian orbits from a kinematic perspective. The aim is to explore the Keplerian parameters for patterns that might imply a nonrandom distribution of the sample. Additionally, various analytical aspects are considered to address the nature of the dusty sources. Methods. Based on the photometric analysis, we estimated the individual H−K and K−L colors for the source sample and compared the results to known cluster members. The classification revealed a noticeable contrast between the S-stars and the dusty sources. To fit the flux-density distribution, we utilized the radiative transfer code HYPERION and implemented a young stellar object Class I model. We obtained the position angle from the Keplerian fit results; additionally, we analyzed the distribution of the inclinations and the longitudes of the ascending node. Results. The colors of the dusty sources suggest a stellar nature consistent with the spectral energy distribution in the near and midinfrared domains. Furthermore, the evaporation timescales of dusty and gaseous clumps in the vicinity of SgrA* are much shorter ( 2yr) than the epochs covered by the observations (≈15yr). In addition to the strong evidence for the stellar classification of the D-sources, we also find a clear disk-like pattern following the arrangements of S-stars proposed in the literature. Furthermore, we find a global intrinsic inclination for all dusty sources of 60 ± 20◦, implying a common formation process. Conclusions. The pattern of the dusty sources manifested in the distribution of the position angles, inclinations, and longitudes of the ascending node strongly suggests two different scenarios: the main-sequence stars and the dusty stellar S-cluster sources share a common formation history or migrated with a similar formation channel in the vicinity of SgrA*. Alternatively, the gravitational influence of SgrA* in combination with a massive perturber, such as a putative intermediate mass black hole in the IRS 13 cluster, forces the dusty objects and S-stars to follow a particular orbital arrangement. Key words. stars: black holes– stars: formation– Galaxy: center– galaxies: star formation
Quality assurance B.pharm 6th semester BP606T UNIT 5
Warehousing
Good warehousing practices
Material management
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...
Wereport the study of a huge optical intraday flare on 2021 November 12 at 2 a.m. UT in the blazar OJ287. In the binary black hole model, it is associated with an impact of the secondary black hole on the accretion disk of the primary. Our multifrequency observing campaign was set up to search for such a signature of the impact based on a prediction made 8 yr earlier. The first I-band results of the flare have already been reported by Kishore et al. (2024). Here we combine these data with our monitoring in the R-band. There is a big change in the R–I spectral index by 1.0 ±0.1 between the normal background and the flare, suggesting a new component of radiation. The polarization variation during the rise of the flare suggests the same. The limits on the source size place it most reasonably in the jet of the secondary BH. We then ask why we have not seen this phenomenon before. We show that OJ287 was never before observed with sufficient sensitivity on the night when the flare should have happened according to the binary model. We also study the probability that this flare is just an oversized example of intraday variability using the Krakow data set of intense monitoring between 2015 and 2023. We find that the occurrence of a flare of this size and rapidity is unlikely. In machine-readable Tables 1 and 2, we give the full orbit-linked historical light curve of OJ287 as well as the dense monitoring sample of Krakow.
Post translation modification by Suyash Garg
overview of PTM helps to the students who wants to clear their basics about it.
Mechanics:- Simple and Compound Pendulum
a compound pendulum is a physical system with a more complex structure than a simple pendulum, incorporating its mass distribution and dimensions into its oscillatory motion around a fixed axis. Understanding its dynamics involves principles of rotational mechanics and the interplay between gravitational potential energy and kinetic energy. Compound pendulums are used in various scientific and engineering applications, such as seismology for measuring earthquakes, in clocks to maintain accurate timekeeping, and in mechanical systems to study oscillatory motion dynamics.
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Music and Medieval History
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
More Related Content
Similar to ANTIMYCOBACTERIAL-DRUGS.pptx
Rifampicin ppt. ravi (medicinal chemistry)
Rifampicin is a semi-synthetic antibiotic produced from Rifamycin-B that is used to treat tuberculosis and other bacterial infections. It works by binding to DNA-dependent RNA polymerase in bacteria, preventing RNA synthesis and protein synthesis. For tuberculosis treatment, rifampicin is used in combination with other drugs in a multi-drug therapy regimen to reduce development of drug resistance. It has good solubility and selectively targets bacterial cells over mammalian cells.
Antitubercular agents (Anti-TB agents)
1. Tuberculosis remains a major global health problem, causing millions of deaths each year. New antitubercular agents are needed to combat drug resistance.
2. The document discusses the development of various classes of antitubercular agents, including synthetic drugs like isoniazid and rifampin, and antibiotics such as streptomycin. It covers their mechanisms of action, effectiveness, and toxicity.
3. Classification of antitubercular drugs includes first-line agents that are most effective and least toxic, second-line alternatives for resistant cases, and third-line options that are least effective and most toxic. Developing improved drug combinations remains a priority area in tuberculosis treatment.
Rifampicin ppt
Rifampicin is a broad-spectrum antibiotic used to treat tuberculosis and other bacterial infections. It works by inhibiting bacterial RNA polymerase, preventing RNA transcription and blocking bacterial growth. Rifampicin is well absorbed orally and widely distributed throughout the body, including crossing the blood-brain barrier. It is metabolized in the liver and mainly eliminated through bile with some excretion in urine. Common side effects include upset stomach, headache, and red/orange discoloration of bodily fluids. Rifampicin may interact adversely with some antiviral, anticoagulant, anti-convulsant and hypoglycemic drugs. It is an important first-line treatment for tuberculosis but requires combination therapy to prevent development
Antiviral HIV ARVS AIDS RETROVIRAL
antiviral,hiv,aids,drugs,infection,cmv,Nonnucleoside,Protease,Integrase,Herpes simplex,Cytomegalovirus,Influenza,immunodeficiency,haart,antiretroviral
mondalanti-viral_drugs_f09.pdf
- The document discusses various antiviral drugs used to treat different viral infections like influenza, herpes simplex virus, cytomegalovirus, hepatitis B, respiratory syncytial virus, and HIV. It provides details on the mechanism of action, pharmacokinetics, therapeutics, and side effects of drugs like amantadine, rimantadine, zanamivir, oseltamivir, acyclovir, ganciclovir, ribavirin, interferons, and lamivudine. It also lists alternative drugs that can be used if the primary drug develops resistance or has unacceptable side effects.
Chapter 10 anti-tb, art...
This document discusses antimycobacterial agents used for treating tuberculosis and leprosy. It notes that mycobacterial infections present challenges as the microbes are slow-growing, can become dormant, and have a lipid-rich cell wall impermeable to many agents. Effective treatment requires prolonged, combined drug regimens to eliminate both actively dividing and resting bacteria and prevent emergence of resistance. First-line agents discussed include isoniazid, rifampin, pyrazinamide, ethambutol, and streptomycin. Adverse effects and mechanisms of action are summarized for each. The document also outlines chemotherapy phases and available drug formulations in Ethiopia.
ANTIMICROBIALS/ ANTIBIOTICS : GENERAL CONSIDERATIONS
Antimicrobial drugs are classified in several ways including based on their chemical structure, mechanism of action, type of organism they target, and spectrum of activity. Some key issues that can arise with antimicrobial use include toxicity, hypersensitivity reactions, drug resistance, and superinfections. When choosing an antimicrobial, factors related to the patient like age, renal/liver function, drug allergies, and pregnancy status must be considered along with drug-related factors like spectrum of activity, toxicity profile, cost, and clinical evidence. The optimal antimicrobial must balance efficacy with safety for each individual patient.
RIFAMPICIN [MEDICINAL CHEMISTRY] BY P.RAVISANKAR.
RIFAMPICIN SOURCE, STRUCTURES,MECHANISM OF ACTION,SAR,RIFAMYCINS, USES HOW T.B IS TREATED?
BY P. RAVISANKAR
VIGNAN PHARMACY COLLEGE
VADLAMUDI
GUNTUR,
ANDHRA PRADESH
INDIA.
TB and Leprosy.pptx
Leprosy
Tuberculosis
TYB pharmacy
Pharmacology semester VI notes
Pharmacology VI semester
Pharmacology notes
Third year B pharmacy pharmacology notes
Pharmacology unit 3 notes
Pharmacology VI semester notes
Anti tb drugs cbme 2021 satya
This interesting ppt contains Anti TB drugs topic for II MBBS CBME students Illustrated with pictures and flowcharts..
Primary headache
The document provides an overview of the classification and treatment of primary headaches according to the International Headache Society. It discusses the four main categories of primary headache - migraine, tension-type headache, trigeminal autonomic cephalalgias (TACs), and other headaches. For each category, it provides the diagnostic criteria and recommendations for treatment, including acute and preventive pharmacological management. The treatment sections cover over-the-counter and prescription medications such as NSAIDs, triptans, antidepressants, anticonvulsants, and other therapeutic options.
Tuberculosis
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis and commonly affects the lungs. It can be transmitted through airborne droplets when an infected person coughs or sneezes. TB is diagnosed through chest x-rays, sputum examination, tuberculin tests, and PCR analysis. The first-line drugs isoniazid, rifampin, pyrazinamide, and ethambutol are used to treat TB according to standard 6-month regimens recommended by the WHO. These drugs work by inhibiting cell wall synthesis and other critical bacterial processes. While generally safe, they can cause adverse effects like hepatitis, rashes, and neuropathy, requiring monitoring during treatment.
Similar to ANTIMYCOBACTERIAL-DRUGS.pptx (12)
ANTIMICROBIALS/ ANTIBIOTICS : GENERAL CONSIDERATIONS
ANTIMICROBIALS/ ANTIBIOTICS : GENERAL CONSIDERATIONS
Recently uploaded
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Context. The observation of several L-band emission sources in the S cluster has led to a rich discussion of their nature. However, a definitive answer to the classification of the dusty objects requires an explanation for the detection of compact Doppler-shifted Brγ emission. The ionized hydrogen in combination with the observation of mid-infrared L-band continuum emission suggests that most of these sources are embedded in a dusty envelope. These embedded sources are part of the S-cluster, and their relationship to the S-stars is still under debate. To date, the question of the origin of these two populations has been vague, although all explanations favor migration processes for the individual cluster members. Aims. This work revisits the S-cluster and its dusty members orbiting the supermassive black hole SgrA* on bound Keplerian orbits from a kinematic perspective. The aim is to explore the Keplerian parameters for patterns that might imply a nonrandom distribution of the sample. Additionally, various analytical aspects are considered to address the nature of the dusty sources. Methods. Based on the photometric analysis, we estimated the individual H−K and K−L colors for the source sample and compared the results to known cluster members. The classification revealed a noticeable contrast between the S-stars and the dusty sources. To fit the flux-density distribution, we utilized the radiative transfer code HYPERION and implemented a young stellar object Class I model. We obtained the position angle from the Keplerian fit results; additionally, we analyzed the distribution of the inclinations and the longitudes of the ascending node. Results. The colors of the dusty sources suggest a stellar nature consistent with the spectral energy distribution in the near and midinfrared domains. Furthermore, the evaporation timescales of dusty and gaseous clumps in the vicinity of SgrA* are much shorter ( 2yr) than the epochs covered by the observations (≈15yr). In addition to the strong evidence for the stellar classification of the D-sources, we also find a clear disk-like pattern following the arrangements of S-stars proposed in the literature. Furthermore, we find a global intrinsic inclination for all dusty sources of 60 ± 20◦, implying a common formation process. Conclusions. The pattern of the dusty sources manifested in the distribution of the position angles, inclinations, and longitudes of the ascending node strongly suggests two different scenarios: the main-sequence stars and the dusty stellar S-cluster sources share a common formation history or migrated with a similar formation channel in the vicinity of SgrA*. Alternatively, the gravitational influence of SgrA* in combination with a massive perturber, such as a putative intermediate mass black hole in the IRS 13 cluster, forces the dusty objects and S-stars to follow a particular orbital arrangement. Key words. stars: black holes– stars: formation– Galaxy: center– galaxies: star formation
Quality assurance B.pharm 6th semester BP606T UNIT 5
Warehousing
Good warehousing practices
Material management
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...
Wereport the study of a huge optical intraday flare on 2021 November 12 at 2 a.m. UT in the blazar OJ287. In the binary black hole model, it is associated with an impact of the secondary black hole on the accretion disk of the primary. Our multifrequency observing campaign was set up to search for such a signature of the impact based on a prediction made 8 yr earlier. The first I-band results of the flare have already been reported by Kishore et al. (2024). Here we combine these data with our monitoring in the R-band. There is a big change in the R–I spectral index by 1.0 ±0.1 between the normal background and the flare, suggesting a new component of radiation. The polarization variation during the rise of the flare suggests the same. The limits on the source size place it most reasonably in the jet of the secondary BH. We then ask why we have not seen this phenomenon before. We show that OJ287 was never before observed with sufficient sensitivity on the night when the flare should have happened according to the binary model. We also study the probability that this flare is just an oversized example of intraday variability using the Krakow data set of intense monitoring between 2015 and 2023. We find that the occurrence of a flare of this size and rapidity is unlikely. In machine-readable Tables 1 and 2, we give the full orbit-linked historical light curve of OJ287 as well as the dense monitoring sample of Krakow.
Post translation modification by Suyash Garg
overview of PTM helps to the students who wants to clear their basics about it.
Mechanics:- Simple and Compound Pendulum
a compound pendulum is a physical system with a more complex structure than a simple pendulum, incorporating its mass distribution and dimensions into its oscillatory motion around a fixed axis. Understanding its dynamics involves principles of rotational mechanics and the interplay between gravitational potential energy and kinetic energy. Compound pendulums are used in various scientific and engineering applications, such as seismology for measuring earthquakes, in clocks to maintain accurate timekeeping, and in mechanical systems to study oscillatory motion dynamics.
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Music and Medieval History
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Rodents, Birds and locust_Pests of crops.pdf
Mole rat or Lesser bandicoot rat, Bandicotabengalensis
•Head -round and broad muzzle
•Tail -shorter than head, body
•Prefers damp areas
•Burrows with scooped soil before entrance
•Potential rat, one pair can produce more than 800 offspringsin one year
Embracing Deep Variability For Reproducibility and Replicability
Embracing Deep Variability For Reproducibility and ReplicabilityUniversity of Rennes, INSA Rennes, Inria/IRISA, CNRS
Embracing Deep Variability For Reproducibility and Replicability
Abstract: Reproducibility (aka determinism in some cases) constitutes a fundamental aspect in various fields of computer science, such as floating-point computations in numerical analysis and simulation, concurrency models in parallelism, reproducible builds for third parties integration and packaging, and containerization for execution environments. These concepts, while pervasive across diverse concerns, often exhibit intricate inter-dependencies, making it challenging to achieve a comprehensive understanding. In this short and vision paper we delve into the application of software engineering techniques, specifically variability management, to systematically identify and explicit points of variability that may give rise to reproducibility issues (eg language, libraries, compiler, virtual machine, OS, environment variables, etc). The primary objectives are: i) gaining insights into the variability layers and their possible interactions, ii) capturing and documenting configurations for the sake of reproducibility, and iii) exploring diverse configurations to replicate, and hence validate and ensure the robustness of results. By adopting these methodologies, we aim to address the complexities associated with reproducibility and replicability in modern software systems and environments, facilitating a more comprehensive and nuanced perspective on these critical aspects.
https://hal.science/hal-04582287
seed production, Nursery & Gardening.pdf
This presentation offers a general idea of the structure of seed, seed production, management of seeds and its allied technologies. It also offers the concept of gene erosion and the practices used to control it. Nursery and gardening have been widely explored along with their importance in the related domain.
Gadgets for management of stored product pests_Dr.UPR.pdf
Insectsplayamajorroleinthedeteriorationoffoodgrainscausingbothquantitativeandqualitativelosses
Wellprovedthatnogranariescanbefilledwithgrainswithoutinsectsastheharvestedproducecontainegg(or)larvae(or)pupae(or)adultinsectinthembecauseoffieldcarryoverinfestationwhichcannotbeavoidedindevelopingcountrieslikeIndia
Simpletechnologiesfortimelydetectionofinsectsinthestoredproduceandtherebyplantimelycontrolmeasures
JAMES WEBB STUDY THE MASSIVE BLACK HOLE SEEDS
The pathway(s) to seeding the massive black holes (MBHs) that exist at the heart of galaxies in the present and distant Universe remains an unsolved problem. Here we categorise, describe and quantitatively discuss the formation pathways of both light and heavy seeds. We emphasise that the most recent computational models suggest that rather than a bimodal-like mass spectrum between light and heavy seeds with light at one end and heavy at the other that instead a continuum exists. Light seeds being more ubiquitous and the heavier seeds becoming less and less abundant due the rarer environmental conditions required for their formation. We therefore examine the different mechanisms that give rise to different seed mass spectrums. We show how and why the mechanisms that produce the heaviest seeds are also among the rarest events in the Universe and are hence extremely unlikely to be the seeds for the vast majority of the MBH population. We quantify, within the limits of the current large uncertainties in the seeding processes, the expected number densities of the seed mass spectrum. We argue that light seeds must be at least 103 to 105 times more numerous than heavy seeds to explain the MBH population as a whole. Based on our current understanding of the seed population this makes heavy seeds (Mseed > 103 M⊙) a significantly more likely pathway given that heavy seeds have an abundance pattern than is close to and likely in excess of 10−4 compared to light seeds. Finally, we examine the current state-of-the-art in numerical calculations and recent observations and plot a path forward for near-future advances in both domains.
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
Context. The early-type galaxy SDSS J133519.91+072807.4 (hereafter SDSS1335+0728), which had exhibited no prior optical variations during the preceding two decades, began showing significant nuclear variability in the Zwicky Transient Facility (ZTF) alert stream from December 2019 (as ZTF19acnskyy). This variability behaviour, coupled with the host-galaxy properties, suggests that SDSS1335+0728 hosts a ∼ 106M⊙ black hole (BH) that is currently in the process of ‘turning on’. Aims. We present a multi-wavelength photometric analysis and spectroscopic follow-up performed with the aim of better understanding the origin of the nuclear variations detected in SDSS1335+0728. Methods. We used archival photometry (from WISE, 2MASS, SDSS, GALEX, eROSITA) and spectroscopic data (from SDSS and LAMOST) to study the state of SDSS1335+0728 prior to December 2019, and new observations from Swift, SOAR/Goodman, VLT/X-shooter, and Keck/LRIS taken after its turn-on to characterise its current state. We analysed the variability of SDSS1335+0728 in the X-ray/UV/optical/mid-infrared range, modelled its spectral energy distribution prior to and after December 2019, and studied the evolution of its UV/optical spectra. Results. From our multi-wavelength photometric analysis, we find that: (a) since 2021, the UV flux (from Swift/UVOT observations) is four times brighter than the flux reported by GALEX in 2004; (b) since June 2022, the mid-infrared flux has risen more than two times, and the W1−W2 WISE colour has become redder; and (c) since February 2024, the source has begun showing X-ray emission. From our spectroscopic follow-up, we see that (i) the narrow emission line ratios are now consistent with a more energetic ionising continuum; (ii) broad emission lines are not detected; and (iii) the [OIII] line increased its flux ∼ 3.6 years after the first ZTF alert, which implies a relatively compact narrow-line-emitting region. Conclusions. We conclude that the variations observed in SDSS1335+0728 could be either explained by a ∼ 106M⊙ AGN that is just turning on or by an exotic tidal disruption event (TDE). If the former is true, SDSS1335+0728 is one of the strongest cases of an AGNobserved in the process of activating. If the latter were found to be the case, it would correspond to the longest and faintest TDE ever observed (or another class of still unknown nuclear transient). Future observations of SDSS1335+0728 are crucial to further understand its behaviour. Key words. galaxies: active– accretion, accretion discs– galaxies: individual: SDSS J133519.91+072807.4
Recently uploaded (20)
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Quality assurance B.pharm 6th semester BP606T UNIT 5
Quality assurance B.pharm 6th semester BP606T UNIT 5
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...
Evidence of Jet Activity from the Secondary Black Hole in the OJ 287 Binary S...
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
Nutaceuticsls herbal drug technology CVS, cancer.pptx
Nutaceuticsls herbal drug technology CVS, cancer.pptx
acanthocytes_causes_etiology_clinical sognificance-future.pptx
acanthocytes_causes_etiology_clinical sognificance-future.pptx
Embracing Deep Variability For Reproducibility and Replicability
Embracing Deep Variability For Reproducibility and Replicability
Gadgets for management of stored product pests_Dr.UPR.pdf
Gadgets for management of stored product pests_Dr.UPR.pdf
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
ANTIMYCOBACTERIAL-DRUGS.pptx
- 4. strategies for addressing drug resistance
- 5. strategies for addressing drug resistance
- 35. rifampicin: mnemonics Rifampicin RNA polymerase inhibitor Red-orange body fluids Rapid development of resistance Revs up Cytochrome P450 (inducer)
- 59. drugs for leprosy (Hansen disease)
- 60. drugs for leprosy (Hansen disease)
- 68. Thank You!